medigraphic.com
ISSN 0028-3851 (Print)

2023, Number 2

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2023; 51 (2)

Disease-modifying therapies in multiple sclerosis

Plascencia-Álvarez NI

Language: Spanish
References: 25
Page: 62-66
PDF size: 215.62 Kb.





REFERENCES

  1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16 (11): 877-897.

  2. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018; 378: 169-180.

  3. Marziniak M, Ghorab K, Kozubski W, Pfleger C, Sousa L, Vernon K, et al. Variations in multiple sclerosis practice within Europe - is it time for a new treatment guideline? Mult Scler Relat Disord. 2016; 8: 35-44.

  4. Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, et al. Serum neurofilament light chain levels in patients with pre symptomatic multiple sclerosis. JAMA Neurol. 2020; 77: 58-64.

  5. Rojas JI, Patrucco L, Míguez J, Besada C, Cristiano E. Brain atrophy in radiologically isolated syndromes. J Neuroimaging. 2015; 25 (1): 68-71.

  6. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010; 74: 1868-1876.

  7. Bovis F, Carmisciano L, Signori A, Pardini M, SteinermanJR, Li T, et al. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. BMC Med. 2019; 17: 113.

  8. ClinicalTrials.gov. Determining the effectiveness of earLy intensive versus escalation approaches for RRMS (DELIVER-MS). 2018. Available in: https://clinicaltrials.gov/ct2/show/results/NCT03535298

  9. Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, Lubetzki C, Gouider R, et al. Fast multiple sclerosis progression in North Africans: Both genetics and environment matter. Neurology. 2017; 88 (13): 1218-1225.

  10. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993; 116 (Pt 1): 117-134.

  11. Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006; 63 (12): 1686-1691.

  12. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004; 63 (11): 2039-2045.

  13. Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler. 2017; 23 (11): 1554-1557.

  14. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010; 68 (2): 193-203.

  15. Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, et al. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. Neurology. 2017; 89 (24): 2455-2461.

  16. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010; 133 (Pt 7): 1914-1929.

  17. Tintore M, Rovira A, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015; 138 (Pt 7): 1863-1874.

  18. Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Spulber G, Wahlund LO, et al. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. J Neuroimmunol. 2014; 274 (1-2): 149-154.

  19. Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016; 22 (12): 1550-1559.

  20. Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016; 15 (6): 574-584.

  21. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019; 15 (5): 287-300.

  22. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013; 40 (3): 307-323.

  23. Gallo P, Van Wijmeersch B; ParadigMS Group. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur J Neurol. 2015; 22 Suppl 2: 14-21.

  24. Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis. diseases-modifying therapies. Continuum (Minneap Minn). 2019; 25 (3): 715-735.

  25. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018; 90 (17): 777-788.




2020     |     www.medigraphic.com